ReviewThe Journal of antibiotics2018
Potential targets for the development of new antifungal drugs.
Review in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- An Antifungal with a Novel Mechanism of Action Discovered via Resistance Gene-Guided Genome Mining.ACS central science · 2026Article
- Biotherapeutic Potential of Probiotic YeastIndian journal of microbiology · 2025Article
- Expression of mannanase and glucanases in lettuce chloroplasts and functional evaluation of enzyme cocktail against Candida albicans in oral cancer patient samples.Plant biotechnology journal · 2025Article
- Is a Fungal Apocalypse Inevitable or Just a Hallucination? An Overview of the Antifungal Armamentarium Used in the Fight against Pathogenic Fungi.ACS medicinal chemistry letters · 2025Review
- From Nature to Drug: Overview and CADD Approach of Anacardic Acid to Propose their Biological Potential.Current topics in medicinal chemistry · 2025Review
- The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chemical biology & drug design · 2025Review
- Discovery of novel targets for important human and plant fungal pathogens via an automated computational pipeline HitList.PloS one · 2025Article
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
- Late-stage diversification of bacterial natural products through biocatalysis.Frontiers in bioengineering and biotechnology · 2024Review
- A Novel Mitochondrial Targeted Compound Phosundoxin Showing Potent Antifungal Activity against Common Clinical Pathogenic Fungi.Journal of fungi (Basel, Switzerland) · 2023Article
- Discovery of Novel Myristic Acid Derivatives as N-Myristoyltransferase Inhibitors: Design, Synthesis, Analysis, Computational Studies and Antifungal Activity.Antibiotics (Basel, Switzerland) · 2023Article
- Blapstin, a Diapause-Specific Peptide-Like Peptide from the Chinese Medicinal BeetleMicrobiology spectrum · 2023Article
- Antifungal activity of the repurposed drug disulfiram againstFrontiers in pharmacology · 2023Article
- Article
- Lycorine Alkaloid andMolecules (Basel, Switzerland) · 2022Article
- Inteins as Drug Targets and Therapeutic Tools.Frontiers in molecular biosciences · 2022Review
- Design, Synthesis, andACS omega · 2021Article
- Aiming for a bull's-eye: Targeting antifungals to fungi with dectin-decorated liposomes.PLoS pathogens · 2021Review
- Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Post-Translational Modifications Drive Success and Failure of Fungal-Host Interactions.Journal of fungi (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, incidences of invasive fungal infections have greatly increased, especially in immunosuppressed patients, but most today's antifungal drugs are not completely effective due to the development of drug resistance, as well as potential toxicity and adverse effects. Consequently, it is imperative to search for novel antifungal agents to combat fungal infections. This review will discuss the advances in the traditional antifungal therapy, and present an overview of novel strategies for the treatment of fungal infections. The papers presented here highlight new targets that could be exploited for development of new antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.